Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2014

01-11-2014 | Review

STEAP4 and insulin resistance

Authors: Xiaoling Chen, Zhiqing Huang, Bo Zhou, Huan Wang, Gang Jia, Guangmang Liu, Hua Zhao

Published in: Endocrine | Issue 2/2014

Login to get access

Abstract

Obesity is a multifactorial disease that caused by the interactions between genetic susceptibility genes and environmental cues. Obesity is considered as a major risk factor of insulin resistance. STEAP4 is a novel anti-obesity gene that is significantly down-regulated in adipose tissue of obese patients. Over-expression of STEAP4 can improve glucose uptake and mitochondrial function, and increase insulin sensitivity. STEAP4 expression is regulated by a variety of inflammatory cytokines, hormones, or adipokines. In this review, we discuss function of STEAP4 in regulating insulin resistance in adipose tissue in vivo, as well as in adipocytes in vitro.
Literature
1.
A. Must, J. Spadano, E.H. Coakley et al., The disease burden associated with overweight and obesity. JAMA 282, 1523–1529 (1999)PubMedCrossRef
2.
A. Mokdad, E.S. Ford, B.A. Bowman et al., Prevalence of obesity, diabetes, and obesity-related health risk factors. JAMA 289, 76–79 (2003)PubMedCrossRef
3.
J.M. Stephens, J. Lee, P.F. Pilch, Tumor necrosis factor-alphainduced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J. Biol. Chem. 272, 971–976 (1997)PubMedCrossRef
4.
H. Kanda, S. Tateya, Y. Tamori et al., MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Investig. 116, 1494–1505 (2006)PubMedCrossRefPubMedCentral
5.
S. Glund, A. Deshmukh, Y.C. Long et al., Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes 56, 1630–1637 (2007)PubMedCrossRef
6.
J. Jager, T. Grémeaux, M. Cormont et al., Interleukin-1β-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinol. J. 148, 241–251 (2007)CrossRef
7.
8.
K.E. Wellen, R. Fucho, M.F. Gregor et al., Coordinated regulation of nutrient and inflammatory response by STAMP2 (STEAP4) is essential for metabolic homeostasis. Cell 129, 537–548 (2007)PubMedCrossRefPubMedCentral
9.
C.M. Zhang, X. Chi, B. Wang et al., Downregulation of STEAP4, a highly-expressed TNF-α-inducible gene in adipose tissue, is associated with obesity in human. Acta Pharmacol. Sin. 29, 587–592 (2008)PubMedCrossRef
10.
J.M. Moreno-Navarrete, F. Ortega, M. Serrano et al., Decreased STAMP2 expression in association with visceral adipose tissue dysfunction. J. Clin. Endocrinol. Metab. 96, E1816–E1825 (2011)PubMedCrossRef
11.
L. Han, M.X. Tang, Z.H. Wang et al., Overexpressing STAMP2 improves insulin resistance in diabetic ApoE−/−/LDLR−/− mice via macrophage polarization shift in adipose tissues. PLoS ONE 8, e78903 (2013)PubMedCrossRefPubMedCentral
12.
P. Arner, B.M. Stenson, E. Dungner et al., Expression of six transmembrane protein of prostate 2 in human adipose tissue associates with adiposity and insulin resistance. J. Clin. Endocrinol. Metab. 93, 2249–2254 (2008)PubMedCrossRef
13.
V. Catalán, J. Gómez-Ambrosi, A. Rodŕguez et al., Six-transmembrane epithelial antigen of prostate 4 and neutrophil gelatinase-associated lipocalin expression in visceral adipose tissue is related to iron status and inflammation in human obesity. Eur. J. Nutr. 52, 1587–1595 (2013)PubMedCrossRef
14.
M. Moldes, F. Lasnier, X. Gauthereau et al., Tumor necrosis factor-α-induced adipose-related protein (TIARP), a cell-surface protein that is highly induced by tumor necrosis factor-α and adipose conversion. J. Biol. Chem. 276, 33938–33946 (2001)PubMedCrossRef
15.
X. Chen, C. Zhu, C. Ji et al., STEAP4, a gene associated with insulin sensitivity, is regulated by several adipokines in human adipocytes. Int. J. Mol. Med. 25, 361–367 (2010)PubMed
16.
S. Kralisch, G. Sommer, S. Weise et al., Interleukin-1beta is a positive regulator of TIARP/STAMP2 gene and protein expression in adipocytes in vitro. FEBS Lett. 583, 1196–1200 (2009)PubMedCrossRef
17.
C.J. Narvaez, K.M. Simmons, J. Brunton et al., Induction of STEAP4 correlates with 1,25-dihydroxyvitamin D3 stimulation of adipogenesis in mesenchymal progenitor cells derived from human adipose tissue. J. Cell. Physiol. 228, 2024–2036 (2013)PubMedCrossRef
18.
19.
M. Fasshauer, J. Klein, S. Krahlisch et al., GH is a positive regulator of tumor necrosis factor α-induced adipose related protein in 3T3-L1 adipocytes. J. Endocrinol. 178, 523–531 (2003)PubMedCrossRef
20.
R.S. Hubert, I. Vivanco, E. Chen et al., STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. PNAS 96, 14523–14528 (1999)PubMedCrossRefPubMedCentral
21.
K.P. Porkka, M.A. Helenius, T. Visakorpi, Cloning and characterization of a novel six-transmembrane protein STEAP2, expressed in normal and malignant prostate. Lab. Investig. 82, 1573–1582 (2002)PubMedCrossRef
22.
K.P. Porkka, N.N. Nupponen, T.L. Tammela et al., Human pHyde is not a classical tumor suppressor gene in prostate cancer. Int. J. Cancer 106, 729–735 (2003)PubMedCrossRef
23.
C.G. Korkmaz, K.S. Korkmaz, P. Kurys et al., Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer. Oncogene 24, 4934–4945 (2005)PubMedCrossRef
24.
J. Qiu, Y.H. Ni, H.X. Gong et al., Identification of differentially expressed genes in omental adipose tissues of obese patients by suppression subtractive hybridization. Biochem. Biophys. Res. Commun. 352, 469–478 (2007)PubMedCrossRef
25.
G.H. Gauss, M.D. Kleven, A.K. Sendamarai et al., The Crystal structure of six transmembrane antigen of the prostate 4 (STEAP4), a ferri/cuprireductase, suggests a novel inter-domain flavin binding site. J. Biol. Chem. 288, 20668–20682 (2013)PubMedCrossRefPubMedCentral
26.
R.S. Ohgami, D.R. Campagna, E.L. Gree et al., Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat. Genet. 37, 1264–1269 (2005)PubMedCrossRefPubMedCentral
27.
A.K. Sendamarai, R.S. Ohgami, M.D. Fleming et al., Structure of the membrane proximal oxidoreductase domain of human STEAP3, the dominant ferrireductase of the erythroid transferrin cycle. Proc. Natl. Acad. Sci. USA 105, 7410–7415 (2008)PubMedCrossRefPubMedCentral
28.
E. Warkentin, B. Mamat, M. Sordel-Klippert et al., Structures of F420H2:NADP+ oxidoreductase with and without its substrates bound. EMBO J. 20, 6561–6569 (2001)PubMedCrossRefPubMedCentral
29.
X. Zhang, K. Krause, I. Xenarios et al., Evolution of the ferric reductase domain (FRD) superfamily: modularity, functional diversification, and signature motif. PLoS ONE 8, e58126 (2013)PubMedCrossRefPubMedCentral
30.
M. Fasshauer, S. Kralisch, M. Klier et al., Interleukin-6 is a positive regulator of tumor necrosis factor K-induced adipose-related protein in 3T3-L1 adipocytes. FEBS Lett. 560, 153–157 (2004)PubMedCrossRef
31.
M.J. Birnbaum, Identification of a novel gene encoding an insulin responsive glucose transporter protein. Cell 57, 305–315 (1989)PubMedCrossRef
32.
M. Mueckler, Facilitative glucose transporters. FEBS Eur. J. Biochem. 219, 713–725 (1994)CrossRef
33.
M. Kanzaki, Insulin receptor signals regulating GLUT4 translocation and actin dynamics. Endocr. J. 53, 267–293 (2006)PubMedCrossRef
34.
D.N. Qin, C.Z. Kou, Y.H. Ni et al., Monoclonal antibody to the six-transmembrane epithelial antigen of prostate 4 promotes apoptosis and inhibits proliferation and glucose uptake in human adipocytes. Int. J. Mol. Med. 26, 803–811 (2010)PubMed
35.
R. Cheng, J. Qiu, X. Zhou et al., Knockdown of STEAP4 inhibits insulin-stimulated glucose transport and GLUT4 translocation via attenuated phosphorylation of Akt, independent of the effects of EEA1. Mol. Med. Rep. 4, 519–523 (2011)PubMed
36.
D. Qin, J. Zhu, C. Ji et al., Monoclonal antibody to six transmembrane epithelial antigen of prostate-4 influences insulin sensitivity by attenuating phosphorylation of P13 K (P85) and Akt: possible mitochondrial mechanism. J. Bioenerg. Biomembr. 43, 247–255 (2011)PubMedCrossRef
37.
J. Gao, X.Y. Wu, C. Owyang et al., Enhanced responses of the anterior cingulate cortex neurons to colonic distension in viscerally hypersensitive rats. J. Physiol. 570, 169–183 (2006)PubMedCrossRefPubMedCentral
38.
39.
Q. Chen, E.J. Vazquez, S. Moghaddas et al., Production of reactive oxygen species by mitochondria. J. Biol. Chem. 278, 36027–36031 (2003)PubMedCrossRef
40.
T. von Rozycki, M.R. Yen, E.E. Lende et al., The YedZ family: possible heme binding proteins that can be fused to transporters and electron carriers. J. Mol. Microbiol. Biotechnol. 8, 129–140 (2004)CrossRef
41.
J.D. Lambeth, NOX enzymes and the biology of reactive oxygen. Nat. Rev. Immunol. 4, 181–189 (2004)PubMedCrossRef
42.
T.G.P. Grunewald, I. Diebold, I. Esposito et al., STEAP1 is associated with the invasive and oxidative stress phenotype of ewing tumors. Mol. Cancer Res. 10, 52–65 (2012)PubMedCrossRef
43.
Y. Pan, Y. Li, L. Guo et al., Influence of expression of six transmembrane epithelial antigen of the prostate-1 on intracellular reactive oxygen species level and cell growth. Natl. Med. J. China 88, 641–644 (2008)
44.
L. Thelander, A. Graslund, M. Thelander, Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem. Biophys. Res. Commun. 110, 859–865 (1983)PubMedCrossRef
45.
R. Lill, K. Diekert, A. Kaut et al., The essential role of mitochondria in the biogenesis of cellular iron-sulfur proteins. Biol. Chem. 380, 1157–1166 (1999)PubMedCrossRef
46.
L.J. Cartier, Y. Ohira, M. Chen et al., Perturbation of mitochondrial composition in muscle by iron deficiency. Implications regarding regulation of mitochondrial assembly. J. Biol. Chem. 261, 13827–13832 (1986)PubMed
47.
A. Latifi, R. Jeanjean, S. Lemeille et al., Iron starvation leads to oxidative stress in Anabaena sp. strain PCC 7120. J. Bacteriol. 187, 6596–6598 (2005)PubMedCrossRefPubMedCentral
48.
T.G.P. Grunewald, H. Bach, A. Cossarizza et al., The STEAP protein family: versatile oxidoreductases and targets for cancer immunotherapy with overlapping and distinct cellular functions. Biol. Cell 104, 641–657 (2012)PubMedCrossRef
49.
P. Ramadoss, F. Chiappini, M. Bilban et al., Regulation of hepatic six transmembrane epithelial antigen of prostate 4 (STEAP4) expression by STAT3 and CCAAT/enhancer-binding protein alpha. J. Biol. Chem. 285, 16453–16466 (2010)PubMedCrossRefPubMedCentral
50.
N. Konstantopoulos, V.C. Foletta, D.H. Segal et al., A gene expression signature for insulin resistance. Physiol. Genomics 43, 110–120 (2011)PubMedCrossRef
51.
H. ten Freyhaus, E.S. Calay, A. Yalcin et al., Stamp2 controls macrophage inflammation through nicotinamide adenine dinucleotide phosphate homeostasis and protects against atherosclerosis. Cell Metab. 16, 81–89 (2012)PubMedCrossRefPubMedCentral
52.
H.Y. Kim, H.K. Cho, S.K. Yoo et al., Hepatic STAMP2 decreases hepatitis B virus X protein-associated metabolic deregulation. Exp. Mol. Med. 44, 622–632 (2012)PubMedCrossRefPubMedCentral
53.
S.B. Wang, T. Lei, L.L. Zhou et al., Functional analysis and transcriptional regulation of porcine six transmembrane epithelial antigen of prostate 4 (STEAP4) gene and its novel variant in hepatocytes. Int. J. Biochem. Cell Biol. 45, 612–620 (2013)PubMedCrossRef
54.
N. Li, Y. Guo, H. Wand et al., Variations of six transmembrane epithelial antigen of prostate 4 (STEAP4) gene are associated with metabolic syndrome in a female Uygur general population. Arch. Med. Res. 41, 449–456 (2010)CrossRef
55.
Y.Y. Guo, N.F. Li, C.M. Wang et al., Genetic variation and association of STEAP4 gene with metabolic syndrome in Chinese Uygur patients. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 28, 78–82 (2011)PubMed
56.
Y.Y. Guo, N.F. Li, L. Zhou et al., A common variation within the STEAP4 gene exons is associated with obesity in Uygur general population. Chin. Med. J. (Engl.) 124, 2096–2100 (2011)
57.
Y.Y. Guo, L. Zhou, X.G. Yao et al., Association of STEAP4 genetic polymorphisms with insulin resistance in Uygur Chinese General Population. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 33, 299–305 (2011)PubMed
58.
R. Han, X. Zhang, Z. Yan et al., Association between genetic polymorphism of the six-transmembrane protein of prostate 2 and obesity in Uygur. Chin. J. Cardiol. 40, 1024–1029 (2012)
59.
W. Zhang, M. Tang, M. Zhong et al., Association of the six transmembrane protein of prostate 2 gene polymorphisms with metabolic syndrome in Han Chinese population. Diabetes Metab. Syndr. 7, 138–142 (2013)PubMedCrossRef
60.
A. Miot, S. Maimaitiming, N. Emery et al., Genetic variability at the six transmembrane protein of prostate 2 locus and the metabolic syndrome: the data from an epidemiological study on the Insulin Resistance Syndrome (DESIR) study. J. Clin. Endocrinol. Metab. 95, 2942–2947 (2010)PubMedCrossRef
61.
T. Wangensteen, H. Akselsen, J. Holmen et al., A common haplotype in NAPEPLD is associated with severe obesity in a Norwegian population-based cohort (the HUNT study). Obesity 19, 612–617 (2011)PubMedCrossRef
62.
A. Inoue, I. Matsumoto, K. Iwanami et al., The role of TNFalpha-induced adipose-related protein (TIARP) in TNF alpha dependent arthritic model-GPI-induced arthritis. Nihon Rinsho Meneki Gakkai Kaishi 32, 15–19 (2009)PubMedCrossRef
63.
A. Inoue, I. Matsumoto, Y. Tanaka et al., Tumor necrosis factor alpha-induced adipose-related protein expression in experimental arthritis and rheumatoid arthritis. Arthr. Res. Ther. 11, R118 (2009)CrossRef
64.
A. Inoue, I. Matsumoto, Y. Tanaka et al., Crucial role of TNFalpha-induced adipose-related protein (TIARP) in the pathogenesis of autoimmune arthritis. Nihon Rinsho Meneki Gakkai Kaishi 35, 51–55 (2012)PubMedCrossRef
65.
Y. Tanaka, I. Matsumoto, K. Iwanami et al., Six-transmembrane epithelial antigen of prostate 4 (STEAP4) is expressed on monocytes/neutrophils, and is regulated by TNFantagonist in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 30, 99–102 (2012)PubMed
66.
Y. Tanaka, I. Matsumoto, K. Iwanami et al., Six-transmembrane epithelial antigen of prostate4 (STEAP4) is a tumor necrosis factor alpha-induced protein that regulates IL-6, IL-8, and cell proliferation in synovium from patients with rheumatoid arthritis. Mod. Rheumatol. 22, 128–136 (2012)PubMedCrossRef
67.
G. Corona, M. Monami, G. Rastrelli et al., Testosterone and metabolic syndrome: a meta-analysis study. J. Sex. Med. 8, 272–283 (2011)PubMedCrossRef
68.
L. Vignozzi, A. Morelli, E. Sarchielli et al., Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J. Endocrinol. 212, 71–84 (2012)PubMedCrossRef
69.
E. Maneschi, A. Morelli, S. Filippi et al., Testosterone treatment improves metabolic syndrome-induced adipose tissue derangements. J. Endocrinol. 215, 347–362 (2012)PubMedCrossRef
70.
S.P. Weisberg, D. McCann, M. Desai et al., Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Investig. 112, 1796–1808 (2003)PubMedCrossRefPubMedCentral
71.
E. Dalmas, K. Clément, M. Guerre-Millo, Defining macrophage phenotype and function in adipose tissue. Trends Immunol. 32, 307–314 (2011)PubMedCrossRef
72.
V. Bourlier, A. Zakaroff-Girard, A. Miranville et al., Remodeling phenotype of human subcutaneous adipose tissue macrophages. Circulation 117, 806–815 (2008)PubMedCrossRef
73.
S. Fujisaka, I. Usui, A. Bukhari et al., Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 58, 2574–2582 (2009)PubMedCrossRefPubMedCentral
74.
M.H. Mendler, B. Turlin, R. Moirand et al., Insulin resistance-associated hepatic iron overload. Gastroenterology 117, 1155–1163 (1999)PubMedCrossRef
75.
J.M. Fernández-Real, A. López-Bermejo, W. Ricart, Crosstalk between iron metabolism and diabetes. Diabetes 51, 2348–2354 (2002)PubMedCrossRef
76.
W.H. Sheu, Y.T. Chen, W.J. Lee et al., A relationship between serum ferritin and the insulin resistance syndrome is present in non-diabetic women but not in non-diabetic men. Clin. Endocrinol. 58, 380–385 (2003)CrossRef
77.
O. Phinas-Hamiel, R.S. Newfield, I. Koren et al., Greater prevalence of iron deficiency in overweight and obese children and adolescents. Int. J. Obes. 27, 416–418 (2003)CrossRef
78.
L.B. Yanoff, C.M. Menzie, B. Denkinger et al., Inflammation and iron deficiency in the hypoferremia of obesity. Int. J. Obes. 31, 1412–1419 (2007)CrossRef
79.
C.M. Menzie, L.B. Yanoff, B.I. Denkinger et al., Obesity-related hypoferremia is not explained by differences in reported intake of heme and nonheme iron or intake of dietary factors that can affect iron absorption. J. Am. Diet. Assoc. 108, 145–148 (2008)PubMedCrossRefPubMedCentral
80.
M.W. Richardson, L. Ang, P.F. Visintainer et al., The abnormal measures of iron homeostasis in pediatric obesity are associated with the inflammation of obesity. Int. J. Pediatr. Endocrinol. 2009, 713269 (2009)PubMedCrossRefPubMedCentral
81.
M. Muńoz, F. Botella-Romero, S. Gómez-Ramírez et al., Iron deficiency and anaemia in bariatric surgical patients: causes, diagnosis and proper management. Nutr. Hosp. 24, 640–654 (2009)PubMed
82.
E.M. Del Giudice, N. Santoro, A. Amato et al., Hepcidin in obese children as a potential mediator of the association between obesity and iron deficiency. J. Clin. Endocrinol. Metab. 94, 5102–5127 (2009)PubMedCrossRef
83.
I. Aeberli, R.F. Hurrell, M.B. Zimmermann, Overweight children have higher circulating hepcidin concentrations and lower iron status but have dietary iron intakes and bioavailability comparable with normal weight children. Int. J. Obes. 33, 1111–1117 (2009)CrossRef
84.
S. Bekri, P. Gual, R. Anty et al., Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 131, 788–796 (2006)PubMedCrossRef
85.
B. Chung, P. Matak, A.T. McKie et al., Leptin regulates the expression of the iron regulatory hormone hepcidin in HuH7 human hepatoma cells. J. Nutr. 137, 2366–2370 (2007)PubMed
86.
C. Zafon, A. Lecube, R. Simó, Iron in obesity. An ancient micronutrient for a modern disease. Obes. Rev. 11, 322–328 (2010)PubMedCrossRef
87.
M.D. Knutson, Steap proteins: implications for iron and copper metabolism. Nutr. Rev. 65, 335–340 (2007)PubMedCrossRef
88.
K. Gkouvatsos, G. Papanikolaou, K. Pantopoulos, Regulation of iron transport and the role of transferrin. Biochim. Biophys. Acta 1820, 188–202 (2012)PubMedCrossRef
89.
J. Zhou, S. Ye, T. Fujiwara et al., STEAP4 plays a critical role in osteoclastogenesis in vitro by regulating cellular iron/ROS levels and CREB activation. J. Biol. Chem. (2013). doi:10.​1074/​jbc.​M113.​478750
90.
Y. Nose, B.E. Kim, D.J. Thiele, Ctr1 drives intestinal copper absorption and is essential for growth, iron metabolism, and neonatal cardiac function. Cell Metab. 4, 235–244 (2006)PubMedCrossRef
91.
A.T. McKie, D. Barrow, G.O. Latunde-Dada et al., An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 291, 1755–1759 (2001)PubMedCrossRef
92.
S. Wyman, R.J. Simpson, A.T. McKie et al., Dcytb (Cybrd1) functions as both a ferric and a cupric reductase in vitro. FEBS Lett. 582, 1901–1906 (2008)PubMedCrossRef
93.
D.J. Pillion, S.J. Kim, H. Kim et al., Insulin signal transduction: the role of protein phosphorylation. Am. J. Med. Sci. 303, 40–52 (1992)PubMedCrossRef
94.
V. Patki, J. Buxton, A. Chawla et al., Insulin action on GLUT4 traffic visualized in single 3T3-L1 adipocytes by using ultra-fast microscopy. Mol. Biol. Cell 12, 129–141 (2001)PubMedCrossRefPubMedCentral
95.
Metadata
Title
STEAP4 and insulin resistance
Authors
Xiaoling Chen
Zhiqing Huang
Bo Zhou
Huan Wang
Gang Jia
Guangmang Liu
Hua Zhao
Publication date
01-11-2014
Publisher
Springer US
Published in
Endocrine / Issue 2/2014
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0230-1

Other articles of this Issue 2/2014

Endocrine 2/2014 Go to the issue

Original Article

Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria

Original Article

Prevention of macrovascular disease in patients with short-duration type 2 diabetes by multifactorial target control: an 8-year prospective study

Mini Review

The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations

Research Letter

Ultrasound-guided percutaneous ethanol injection in papillary thyroid cancer metastatic lymph-nodes

Letter to the Editor

Tumor-like pyogenic liver abscess caused by Klebsiella pneumoniae in diabetes

Editorial

Thyroid fine-needle aspiration: the relevance of BRAF mutation testing
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits